Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9842901rdf:typepubmed:Citationlld:pubmed
pubmed-article:9842901lifeskim:mentionsumls-concept:C0167627lld:lifeskim
pubmed-article:9842901lifeskim:mentionsumls-concept:C0752087lld:lifeskim
pubmed-article:9842901lifeskim:mentionsumls-concept:C1332709lld:lifeskim
pubmed-article:9842901lifeskim:mentionsumls-concept:C0443199lld:lifeskim
pubmed-article:9842901lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:9842901lifeskim:mentionsumls-concept:C1514873lld:lifeskim
pubmed-article:9842901pubmed:issue11lld:pubmed
pubmed-article:9842901pubmed:dateCreated1998-12-17lld:pubmed
pubmed-article:9842901pubmed:abstractTextThe interactions of CD28-B7 and CD40-CD40 ligand (CD40L) pathways in T cell costimulation and autoimmune disease are incompletely understood. We sought to address this issue by investigation of the genesis of acetylcholine receptor (AChR)-induced antibody-mediated experimental autoimmune myasthenia gravis (EAMG) in CD28- and CD40L-deficient mice (CD28-/-, CD40L-/-). Compared to wild-type mice, the CD28-/- mice became less susceptible, and CD40L-/- mice were completely resistant to EAMG induction. Analysis of T helper functions, reflected by cytokine responses, revealed a switch to a Th1 profile in CD28-/- mice. Consistently, levels of serum AChR-specific antibodies of the IgG1 isotype were decreased in CD28-/- mice. In the CD40L-/- mice, both Th1 and Th2 cytokine responses were diminished, and T cell-dependent AChR-reactive B cell responses were more severely impaired than in the CD28-/- mice. Thus, CD28 and CD40L are differentially required for induction of EAMG.lld:pubmed
pubmed-article:9842901pubmed:languageenglld:pubmed
pubmed-article:9842901pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9842901pubmed:citationSubsetIMlld:pubmed
pubmed-article:9842901pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9842901pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9842901pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9842901pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9842901pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9842901pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9842901pubmed:statusMEDLINElld:pubmed
pubmed-article:9842901pubmed:monthNovlld:pubmed
pubmed-article:9842901pubmed:issn0014-2980lld:pubmed
pubmed-article:9842901pubmed:authorpubmed-author:LindAAlld:pubmed
pubmed-article:9842901pubmed:authorpubmed-author:LiHHlld:pubmed
pubmed-article:9842901pubmed:authorpubmed-author:FOXJ FJFlld:pubmed
pubmed-article:9842901pubmed:authorpubmed-author:LjunggrenH...lld:pubmed
pubmed-article:9842901pubmed:authorpubmed-author:GouZ YZYlld:pubmed
pubmed-article:9842901pubmed:authorpubmed-author:MatuseviciusD...lld:pubmed
pubmed-article:9842901pubmed:issnTypePrintlld:pubmed
pubmed-article:9842901pubmed:volume28lld:pubmed
pubmed-article:9842901pubmed:ownerNLMlld:pubmed
pubmed-article:9842901pubmed:authorsCompleteYlld:pubmed
pubmed-article:9842901pubmed:pagination3587-93lld:pubmed
pubmed-article:9842901pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:9842901pubmed:meshHeadingpubmed-meshheading:9842901-...lld:pubmed
pubmed-article:9842901pubmed:meshHeadingpubmed-meshheading:9842901-...lld:pubmed
pubmed-article:9842901pubmed:meshHeadingpubmed-meshheading:9842901-...lld:pubmed
pubmed-article:9842901pubmed:meshHeadingpubmed-meshheading:9842901-...lld:pubmed
pubmed-article:9842901pubmed:meshHeadingpubmed-meshheading:9842901-...lld:pubmed
pubmed-article:9842901pubmed:meshHeadingpubmed-meshheading:9842901-...lld:pubmed
pubmed-article:9842901pubmed:meshHeadingpubmed-meshheading:9842901-...lld:pubmed
pubmed-article:9842901pubmed:meshHeadingpubmed-meshheading:9842901-...lld:pubmed
pubmed-article:9842901pubmed:meshHeadingpubmed-meshheading:9842901-...lld:pubmed
pubmed-article:9842901pubmed:meshHeadingpubmed-meshheading:9842901-...lld:pubmed
pubmed-article:9842901pubmed:meshHeadingpubmed-meshheading:9842901-...lld:pubmed
pubmed-article:9842901pubmed:meshHeadingpubmed-meshheading:9842901-...lld:pubmed
pubmed-article:9842901pubmed:year1998lld:pubmed
pubmed-article:9842901pubmed:articleTitleDifferential requirements for CD28 and CD40 ligand in the induction of experimental autoimmune myasthenia gravis.lld:pubmed
pubmed-article:9842901pubmed:affiliationDivision of Neurology, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden. Fu-Dong.Shi@cnsf.ki.selld:pubmed
pubmed-article:9842901pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9842901pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9842901lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9842901lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9842901lld:pubmed